The trial demonstrated an 86% overall survival rate at six months, highlighting the potential impact of the treatment as it continues to mature, which may be contributing to the stock’s stability in early trading.VSTM Stock Catalyst: RAMP 205 Pancreatic Cancer Trial UpdateThe RAMP 205 trial results indicate that 90% of patients presented with metastatic disease at diagnosis, and the combination therapy showed promising clinical activity, including a 68% progression-free survival rate at six months.This news underscores the importance of Verastem’s ongoing research in addressing treatment resistance in pancreatic cancer.At the recommended phase 2 P2D dose, the majority (83%) of patients experienced tumor shrinkage.Nine patients remain on treatment at this dose level.Adverse events remained generally consistent with the previously reported safety and tolerability profile, with no new safety signals observed.On Tuesday, the oncology biopharmaceutical company dosed the first patient in the TARGET-D 201 Phase 2 trial of VS-7375, an investigational oral KRAS G12D (ON/OFF) for KRAS G12D-mutated metastatic pancreatic ductal carcinoma.VSTM Technical Analysis: Trend, Momentum And Key LevelsCurrently, Verastem’s stock price sits at $4.01, which is about 1.1% above its 20-day simple moving average (SMA) of $4.03.The stock remains significantly below its longer-term moving averages, trading 17.9% below the 50-day SMA of $4.96 and 25% below the 100-day SMA of $5.42, indicating a bearish trend overall.The moving average convergence divergence (MACD) is above its signal line, suggesting that downside pressure is easing, which may indicate improving momentum compared to the previous downswing.This positive momentum could support a potential reversal if the stock can maintain its current levels.